GFBiochemicals is the only company to produce levulinic acid derivatives at commercial scale directly from biomass. The company was co-founded in 2010 by Pasquale Granata and Mathieu Flamini.

Our founders worked closely with a group of biobased chemical experts to find sustainable alternatives to oil-based products across a range of market sectors. Together, they developed the production technology needed for this revolution in chemicals, in partnership with the University of Pisa and the Polytechnic University of Milan, the technology’s potential was demonstrated on the plant in Italy which has been retrofitted with new conversion, recovery and purification technology.

GFBiochemicals expects substantial growth in the levulinic acid market in the coming years.

In February 2016, GFBiochemicals acquired Segetis, the leading producer of levulinic acid derivatives, in a move towards downstream integration. This acquisition marked a transformational step for GFBiochemicals enabling the combined business to create high-value derivatives from levulinic acid produced using GFBiochemicals’ patented technology. Segetis provides GFBiochemicals with a market-leading brand and unique intellectual property composed of over 50 patents and over 200 pending patent applications worldwide, as well as a production plant located in Minnesota.

GFBiochemicals headquarter is in Paris, France.

Our team of technical experts have decades of experience in innovation, production and business development. Funded and supported by private investors, GFBiochemicals is committed for the long-term.

In 2020 GFBiochemicals announced a Joint Venture called NXTLEVVEL Biochem, with Towell Engineering Group of Oman for the manufacturing of biosolvants using GFBiochemicals proprietary technology.